Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

In people with Parkinson's disease, neuropsychiatric signs and symptoms are common
throughout the disease course. These symptoms can be disabling and as clinically relevant …

Excessive daytime sleepiness (EDS) is a public health issue. However, it remains largely
undervalued, scarcely diagnosed, and poorly supported. Variations in the definition of EDS …

Braak's hypothesis has been extremely influential over the last two decades. However,
neuropathological and clinical evidence suggest that the model does not conform to all …

Depression is one of the most frequent and burdensome non-motor symptoms in
Parkinson's disease (PD), across all stages. Even when its severity is mild, PD depression …

The way sporadic Parkinson's disease (PD) is perceived has undergone drastic changes in
recent decades. For a long time, PD was considered a brain disease characterized by motor …

Background Cognitive decline occurs frequently in Parkinson's disease (PD), which greatly
decreases the quality of life of patients. However, the mechanisms remain to be investigated …

Sleep disorders (SDs) are common non-motor symptoms of Parkinson's disease (PD) with
wide variability in their prevalence rates. The etiology of SDs in PD is multifactorial because …

Quantifying gait and postural control adds valuable information that aids in understanding
neurological conditions where motor symptoms predominate and cause considerable …

Background: Cannabidiol (CBD) is one of the main components of Cannabis sativa and has
anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on …